Lobeline has multiple mechanisms of action, acting as a [[VMAT2]] ligand,<ref>{{cite journal | pmid=17233532| pmc=2751365| year=2006| author1=Zheng| first1=G| title=Vesicular monoamine transporter 2: Role as a novel target for drug development| journal=The AAPS Journal| volume=8| issue=4| pages=E682–92| last2=Dwoskin| first2=L. P.| last3=Crooks| first3=P. A.| doi=10.1208/aapsj080478}}</ref><ref>{{cite journal | pmid=17331733| pmc=2001191| year=2007| author1=Zheng| first1=F| title=Computational neural network analysis of the affinity of lobeline and tetrabenazine analogs for the vesicular monoamine transporter-2| journal=Bioorganic & Medicinal Chemistry| volume=15| issue=8| pages=2975–92| last2=Zheng| first2=G| last3=Deaciuc| first3=A. G.| last4=Zhan| first4=C. G.| last5=Dwoskin| first5=L. P.| last6=Crooks| first6=P. A.| doi=10.1016/j.bmc.2007.02.013}}</ref><ref>{{cite journal | pmid=16107155| pmc=3617589| year=2005| author1=Zheng| first1=G| title=Defunctionalized lobeline analogues: Structure-activity of novel ligands for the vesicular monoamine transporter| journal=Journal of Medicinal Chemistry| volume=48| issue=17| pages=5551–60| last2=Dwoskin| first2=L. P.| last3=Deaciuc| first3=A. G.| last4=Norrholm| first4=S. D.| last5=Crooks| first5=P. A.| doi=10.1021/jm0501228}}</ref> which stimulates [[dopamine]] release to a moderate extent when administered alone, but reduces the dopamine release caused by [[methamphetamine]].<ref>{{cite journal | pmid=18191815| pmc=2435375| year=2008| author1=Wilhelm| first1=C. J.| title=Lobeline effects on tonic and methamphetamine-induced dopamine release| journal=Biochemical Pharmacology| volume=75| issue=6| pages=1411–5| last2=Johnson| first2=R. A.| last3=Eshleman| first3=A. J.| last4=Janowsky| first4=A| doi=10.1016/j.bcp.2007.11.019}}</ref><ref>{{cite journal | pmid=15102929| year=2004| author1=Wilhelm| first1=C. J.| title=Effects of methamphetamine and lobeline on vesicular monoamine and dopamine transporter-mediated dopamine release in a cotransfected model system| journal=Journal of Pharmacology and Experimental Therapeutics| volume=310| issue=3| pages=1142–51| last2=Johnson| first2=R. A.| last3=Lysko| first3=P. G.| last4=Eshleman| first4=A. J.| last5=Janowsky| first5=A| doi=10.1124/jpet.104.067314}}</ref> It also inhibits the reuptake of dopamine and [[serotonin]],<ref>{{cite journal | pmid=16905316| pmc=3934794| year=2006| author1=Zheng| first1=G| title=Des-keto lobeline analogs with increased potency and selectivity at dopamine and serotonin transporters| journal=Bioorganic & Medicinal Chemistry Letters| volume=16| issue=19| pages=5018–21| last2=Horton| first2=D. B.| last3=Deaciuc| first3=A. G.| last4=Dwoskin| first4=L. P.| last5=Crooks| first5=P. A.| doi=10.1016/j.bmcl.2006.07.070}}</ref> and acts as a mixed [[agonist–antagonist]] at [[nicotinic acetylcholine receptor]]s<ref>{{cite journal | pmid=9223582| year=1997| author1=Damaj| first1=M. I.| title=Pharmacology of lobeline, a nicotinic receptor ligand| journal=The Journal of Pharmacology and Experimental Therapeutics| volume=282| issue=1| pages=410–9| last2=Patrick| first2=G. S.| last3=Creasy| first3=K. R.| last4=Martin| first4=B. R.}}</ref><ref>{{cite journal | pmid=12479946| year=2003| author1=Miller| first1=D. K.| title=Lobeline attenuates locomotor stimulation induced by repeated nicotine administration in rats| journal=Pharmacology, Biochemistry, and Behavior| volume=74| issue=2| pages=279–86| last2=Harrod| first2=S. B.| last3=Green| first3=T. A.| last4=Wong| first4=M. Y.| last5=Bardo| first5=M. T.| last6=Dwoskin| first6=L. P.| doi=10.1016/s0091-3057(02)00996-6}}</ref> to which it binds at the subunit interfaces of the extracellular domain.<ref>PDB entry {{PDBe|2bys}}. {{cite journal | pmid=16193063| pmc=1276711| year=2005| author1=Hansen| first1=S. B.| title=Structures of Aplysia AChBP complexes with nicotinic agonists and antagonists reveal distinctive binding interfaces and conformations| journal=The EMBO Journal| volume=24| issue=20| pages=3635–46| last2=Sulzenbacher| first2=G| last3=Huxford| first3=T| last4=Marchot| first4=P| last5=Taylor| first5=P| last6=Bourne| first6=Y| doi=10.1038/sj.emboj.7600828}}</ref> It is also an [[receptor antagonist|antagonist]] at [[Mu Opioid receptor|μ-opioid receptors]].<ref>{{cite journal | pmid=17368966| year=2007| author1=Miller| first1=D. K.| title=Lobeline, a potential pharmacotherapy for drug addiction, binds to mu opioid receptors and diminishes the effects of opioid receptor agonists| journal=Drug and Alcohol Dependence| volume=89| issue=2–3| pages=282–91| last2=Lever| first2=J. R.| last3=Rodvelt| first3=K. R.| last4=Baskett| first4=J. A.| last5=Will| first5=M. J.| last6=Kracke| first6=G. R.| doi=10.1016/j.drugalcdep.2007.02.003}}</ref> It seems to be a [[P-glycoprotein]] inhibitor, according to at least one study.<ref>{{Cite journal|last=Ma|first=Yonggang|last2=Wink|first2=Michael|date=2008-09-01|title=Lobeline, a piperidine alkaloid from Lobelia can reverse P-gp dependent multidrug resistance in tumor cells|pmid=18222670|journal=Phytomedicine: International Journal of Phytotherapy and Phytopharmacology|volume=15|issue=9|pages=754–758|doi=10.1016/j.phymed.2007.11.028|issn=1618-095X}}</ref> It has been hypothesized that P-glycoprotein inhibition reduces chemotherapeutic resistance in cancer,<ref>{{Cite journal|last=Abdallah|first=Hossam M.|last2=Al-Abd|first2=Ahmed M.|last3=El-Dine|first3=Riham Salah|last4=El-Halawany|first4=Ali M.|date=2016-10-08|title=P-glycoprotein inhibitors of natural origin as potential tumor chemo-sensitizers: A review|pmc=4293676|journal=Journal of Advanced Research|volume=6|issue=1|pages=45–62|doi=10.1016/j.jare.2014.11.008|issn=2090-1232|pmid=25685543}}</ref> presumably affecting any substrates of P-gp.
